GILD

Gilead Sciences에 대한 매도 수량은 투자자에게 Gilead Sciences의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Gilead Sciences (NASDAQ:GILD) 주식, 공매도 수량 보고

GILEAD SCIENCES INC

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Alphabet

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

GOOG

GOOGL

INTC

금요일(25일) 아침 미국 지수 선물이 상승세를 보이고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 일부 주식은 다음과 같다. 알파벳, 인텔, 필립스66, 슐럼버거 및 길리어드 사이언스

금요일 주목해야 할 주식: 알파벳, 인텔, 필립스66, 슐럼버거 및 길리어드 사이언스

Boston,,Massachusetts;,July,7,,2017,:,Holding,A,Truvada,Prep

Biotech

Health Care

After-Hours Center

Movers

General

길리어드 사이언스는 주당 1.81달러의 분기 순이익을 발표했는데, 이는 애널리스트 예상치인 1.76달러를 상회하는 수치다. 분기 매출은 66억 7,000만 달러로 애널리스트 컨센서스 예상치인 67억 7,000만 달러를 하회했으며 전년 동기 매출 66억 9,000만 달러에서 감소했다.

길리어드 사이언스, 엇갈린 1분기 실적 및 하향 조정된 가이던스 제시···시간외 3%↓

Time magazine

Entertainment

Management

Media

NFLX

PLTR

TSLA

도널드 트럼프 대통령이 2024년 타임지의 올해의 인물로 선정되었고, 2025년 타임지 선정 가장 영향력 있는 100인 목록에도 이름을 올렸다.트럼프와 J.D. 밴스, 로버트 F. 케네디 주니어, 하비에르 밀레이와 같은 정치 지도자들 외에도 이 목록에는 여러 상장 미국 기업의 CEO들이 포함되어 있다.

타임지 &#39;올해 가장 영향력 있는 100人&#39;에 일론 머스크, 마크 저커버그, 알렉스 카프 등 선정

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

<a href="https://ca.investing.com/news/stock-market-news/gilead-sciences-shares-hit-after-hiv-studies-placed-on-hold-by-fda-4058215" title="https://ca.investing.com/news/stock-market-news/gilead-sciences-shares-hit-after-hiv-studies-placed-on-hold-by-fda-4058215">https://ca.investing.com/news/stock-market-news/gilead-sciences-shares-hit-after-hiv-studies-placed-on-hold-by-fda-4058215</a>

'FDA Places Clinical Hold On Gilead's HIV Treatment Trials Of GS-1720 And/Or GS-4182; Hold Due To Identification Of Safety Signal Of Decreases In CD4+T-Cell & Absolute Lymphocyte Counts In Subset Of Participants Getting Combo; Intend To Investigate And Pursue Potential Of Both Agents And Work With Regulatory Authorities To Resolve Issues' - Investing

In February, the U.S. Food and Drug Administration (FDA) accepted Gilead Sciences, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) New Drug Application (NDA) submissions for lenacapavir — the company&#8217;s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-<a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">exposure prophylaxis (PrEP)</a>.
What Happened: The FDA will review the applications under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target <a href="https://www.benzinga.com/pressreleases/25/02/b43780305/u-s-fda-accepts-gileads-new-drug-applications-for-twice-yearly-lenacapavir-for-hiv-prevention-unde" target="_blank" rel="noreferrer noopener">action date of June 19, 2025</a>.
In June 2024, Gilead Sciences shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial, indicating its twice-yearly lenacapavir&nbsp;demonstrated 100% efficacy for the investigational use of HIV <a target="_blank" href="https://www.benzinga.com/markets/equities/24/06/39416579/why-is-gilead-sciences-stock-trading-higher-on-thursday" rel="noreferrer noopener">prevention in cisgender women</a>.
Based on these results, the independent Data Monitoring Committee (DMC) recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants.
Since June last year, Gilead stock has gained almost 74%, and year-to-date stock has jumped around 21%.
In March, Gilead Sciences&nbsp;presented data from its HIV treatment portfolio and pipeline at the&nbsp;Conference on Retroviruses and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" rel="noreferrer noopener">Opportunistic Infections&nbsp;(CROI 2025)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44907790/gilead-cancer-drug-combined-with-mercks-drug-effective-in-difficult-to-treat-type-of-breast-cancer" rel="noreferrer noopener">Gilead Cancer Drug Combined With Merck&#8217;s Drug Effective In Difficult To Treat Type Of Breast Cancer</a>
With the breakthrough, Wall Street is paying attention again.
The company, a leader in HIV treatment, is showing signs of a successful turnaround. Despite this momentum, its stock is still relatively cheap, trading at 13.3 times forward earnings — less than the pharmaceutical industry average of 14.
Why It Matters: Some investors may worry that Gilead is repeating history. About 10 years ago, its stock surged due to the success of a cure for hepatitis C, but later, it declined as demand faded. Since then, slow growth and disappointing cancer drug deals hurt its image, making it seem like a value trap.
This time could be different — but Gilead has to deliver.
Over 400,000 Americans use PrEP. To reach $4 billion in annual sales, citing some analysts, the Wall Street Journal <a href="https://www.wsj.com/health/pharma/a-new-shot-prevents-hivand-breathes-new-life-into-a-stagnant-biotech-6badbce9" target="_blank" rel="noreferrer noopener">report</a> expects that by 2030, Gilead must get more people on the drug and grow the market globally. The company aims to more than double U.S. PrEP users to over one million in the next 10 years.
Unlike other drugmakers facing upcoming patent expirations, Gilead is well-positioned. Its HIV drug Biktarvy, used after infection, is protected from generic competition until 2033.
It also has several next-generation HIV treatments in development, supporting its future growth.
In the first quarter of 2025, HIV product sales increased 6% year-over-year <a href="https://www.benzinga.com/general/biotech/25/04/44997817/gilead-sciences-stock-slips-after-mixed-q1-results-lowered-fy25-eps-guidance" target="_blank" rel="noreferrer noopener">to $4.59 billion</a>.
According to a media report in February, the Health and Human Services Department is considering substantial reductions in federal funding for <a href="https://www.benzinga.com/general/biotech/25/03/44395415/trump-administration-weighs-deep-cuts-to-domestic-hiv-prevention-programs-gilead-stock-slides" target="_blank" rel="noreferrer noopener">domestic HIV prevention</a>.
Mitchell Warren, executive director of HIV prevention group AVAC, says the CDC&#8217;s PrEP program could be reduced or cut. Launched last fall as a pilot program, it provides free medication to help prevent HIV.
GILD Price Action: GILD stock is up 2.19% at $111.41 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/06/45791216/citi-to-cut-3500-tech-jobs-in-china-in-global-restructuring-spree" target="_blank" rel="noreferrer noopener">Citi To Cut 3,500 Tech Jobs In China In Global Restructuring Spree</a></li>
</ul>

Photo: Shutterstock

Large Cap

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.99% on an annualized basis producing an average annual return of 12.25%. Currently, Gilead Sciences has a market capitalization of $136.78 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,044.25 today based on a price of $109.96 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748875512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Reported Sunday, Gilead's Kite Presents Real-World Data At ASCO 2025 Supporting Outpatient Use Of Yescarta For R/R Large B-Cell Lymphoma With Comparable Safety And Efficacy

<ul>
<li>First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC –</li>
<li>Early Trend in Improvement in Overall Survival Observed</li>
</ul>

Reported Saturday, Gilead's TROP-2 ADC Trodelvy, In Combination With Keytruda, Shows Clinically Meaningful Survival Gains And Fewer Adverse Event-Related Discontinuations In ASCENT-04

Rumors

Watching Gilead Sciences; Hearing Investor Business Daily's SwingTrader Buys Stock

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$55.00</td>
<td>$71.1K</td>
<td>2.1K</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$25.00</td>
<td>$68.0K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$100.00</td>
<td>$44.0K</td>
<td>1.1K</td>
<td>960</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$630.00</td>
<td>$119.6K</td>
<td>6</td>
<td>705</td>
</tr>
<tr>
<td>VEEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$210.00</td>
<td>$65.7K</td>
<td>534</td>
<td>589</td>
</tr>
<tr>
<td>NVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$115.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>379</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$80.00</td>
<td>$42.5K</td>
<td>883</td>
<td>372</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$295.00</td>
<td>$40.2K</td>
<td>985</td>
<td>344</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$195.00</td>
<td>$25.8K</td>
<td>5.0K</td>
<td>319</td>
</tr>
<tr>
<td>COR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$280.00</td>
<td>$36.4K</td>
<td>762</td>
<td>200</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a put option sweep that happens to be bearish, expiring in 51 day(s) on July 18, 2025. This event was a transfer of 89 contract(s) at a $55.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $71.1K, with a price of $799.0 per contract. There were 2196 open contracts at this strike prior to today, and today 1320 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 1000 contract(s) at a $25.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $68.0K, with a price of $68.0 per contract. There were 2289 open contracts at this strike prior to today, and today 1083 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a put option trade that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 958 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $46.0 per contract. There were 1139 open contracts at this strike prior to today, and today 960 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with neutral sentiment. It expires in 51 day(s) on July 18, 2025. Parties traded 46 contract(s) at a $630.00 strike. The total cost received by the writing party (or parties) was $119.6K, with a price of $2600.0 per contract. There were 6 open contracts at this strike prior to today, and today 705 contract(s) were bought and sold. 
• Regarding VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we observe a put option sweep with bearish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 212 contract(s) at a $210.00 strike. This particular put needed to be split into 45 different trades to become filled. The total cost received by the writing party (or parties) was $65.7K, with a price of $310.0 per contract. There were 534 open contracts at this strike prior to today, and today 589 contract(s) were bought and sold. 
• For NVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), we notice a call option sweep that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 224 contract(s) at a $115.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $125.0 per contract. There were 1879 open contracts at this strike prior to today, and today 379 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option trade that happens to be bearish, expiring in 79 day(s) on August 15, 2025. This event was a transfer of 100 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $42.5K, with a price of $425.0 per contract. There were 883 open contracts at this strike prior to today, and today 372 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 134 contract(s) at a $295.00 strike. The total cost received by the writing party (or parties) was $40.2K, with a price of $300.0 per contract. There were 985 open contracts at this strike prior to today, and today 344 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 137 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $189.0 per contract. There were 5038 open contracts at this strike prior to today, and today 319 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a put option sweep with neutral sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 135 contract(s) at a $280.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $36.4K, with a price of $270.0 per contract. There were 762 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AMGN

MRNA

REGN

VEEV

10 Health Care Stocks Whale Activity In Today's Session

Gilead Sciences Announces Topline Results From Phase 3 ASCENT-03 Study Of Trodelvy Met Its Primary Endpoint

Ratings for Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $128.0, a high estimate of $140.00, and a low estimate of $117.00. This upward trend is evident, with the current average reflecting a 7.56% increase from the previous average price target of $119.00.
<img src="https://www.benzinga.com/files/images/story/2025/1747857620_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Gilead Sciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$117.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$126.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Gilead Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Gilead Sciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Gilead Sciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>Unveiling the Story Behind Gilead Sciences</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Gilead Sciences: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3M period, Gilead Sciences faced challenges, resulting in a decline of approximately -0.28% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Gilead Sciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 19.72%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.83%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Gilead Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 2.28%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Gilead Sciences's debt-to-equity ratio is below the industry average at 1.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Gilead Sciences Stock

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Gilead Sciencesto Hold

– Late-Breaking Data from the Phase 3 ASCENT-04/KEYNOTE-D19 Study Evaluating Trodelvy&#xAE; plus Keytruda&#xAE; in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer –

Events

Gilead And Kite To Present Data In 1L Metastatic Triple-Negative Breast Cancer, Updated Results In Multiple Myeloma And Early Data From  Investigational CAR T-Cell Therapy Targeting Brain Cancer At 2025 ASCO And EHA

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has risen 17.39% since its last report. The company recently reported that it has 23.57 million shares sold short, which is 1.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747321225_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 6.93%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Gilead Sciences?

WIIM

Shares of pharmaceutical stocks are trading lower. The sector may down on continued weakness amid President Trump's drug pricing executive order.

The United States and China agreed to slash their retaliatory tariffs by over 100 percentage points, pausing a spiraling trade war that had threatened<a href="https://www.benzinga.com/news/econ-s"> to choke global growth.</a>
<h3 class="wp-block-heading">What's In The Deal?</h3>
The agreement establishes a 90-day reset, slashing U.S. tariffs on Chinese goods from 145% to 30%, and Chinese tariffs on U.S. goods from 125% to 10%, starting May 14. 
The decision stems from high-level negotiations in Geneva, led by U.S. Treasury Secretary Scott Bessent and China's Vice Premier He Lifeng.
The truce halts one of the steepest protectionist escalations in recent history, following President Donald Trump's aggressive "Liberation Day" trade tariffs launched on April 2.
"We reached an agreement on a 90-day pause and substantially moved down the tariff levels," Bessent said in a press conference. 
"Both countries represented their national interests very well, but we concluded we have shared interest in balanced trade."
<h3 class="wp-block-heading">Tariff Truce Cools Recession And Inflation Risks</h3>
The tariff rollback offers more than diplomatic relief — it also addresses growing fears of a U.S. economic slowdown and resurgent inflation. By averting the triple-digit import taxes that threatened to choke global trade, the deal removes a significant source of economic uncertainty that had weighed on business investment and consumer confidence.
Recession probabilities have sharply declined in response. 
The latest market-based forecast from Kalshi shows a 46% chance of a U.S. recession this year, down from 60% at the end of April, reflecting improving sentiment. Notably, consumer spending and corporate earnings had begun showing early signs of strain under the tariff shock imposed in April.
On the inflation front, the agreement is expected to ease price pressures on goods most impacted by the trade war — including electronics, automotive parts and industrial equipment.
Ahead of Tuesday's official April Consumer Price Index report, economists expect a return to monthly inflation growth: headline prices are forecast to rise 0.3%, reversing March's 0.1% dip. Core inflation is also expected to rise 0.3%, while annual inflation rates are seen holding steady at 2.4% for headline and 2.8% for core.
<h3 class="wp-block-heading">Why Markets Cheered</h3>
U.S. equity futures soared as the news hit, with futures on the S&amp;P 500 climbing 3.13% to 5,836.66, those on the Nasdaq 100 jumping 4.05%, and Dow futures up 2.62%. 
The U.S. dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – surged 1.4%, with the greenback rallying 2% against the Japanese yen. 
Meanwhile, 2-year Treasury yields rose 10 basis points to 4%, as traders dialed back expectations for a near-term Federal Reserve rate cut. The odds of a June cut fell to 11%, down from 25% a week ago, per CME FedWatch.
Gold – as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) – dropped 2.9%, with investors rotating out of safe havens, and oil climbed 3.9% to $63.40 amid improving global demand prospects.
<h3 class="wp-block-heading">Who Wins On Wall Street?</h3>
U.S. equities rallied sharply as investors welcomed the truce between Washington and Beijing. 
Trade-sensitive and consumer-facing stocks led the premarket advance, reflecting relief over lower input costs and reduced supply chain disruption. Technology and industrials also posted notable gains.
Top Gainers – S&amp;P 500
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stanley Black &amp; Decker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>)</td>
<td>+12.07%</td>
</tr>
<tr>
<td>Best Buy Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</td>
<td>+10.42%</td>
</tr>
<tr>
<td>Microchip Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>)</td>
<td>+9.29%</td>
</tr>
<tr>
<td>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>)</td>
<td>+8.94%</td>
</tr>
<tr>
<td>NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</td>
<td>+8.08%</td>
</tr>
</tbody>
</table>
</figure>
Top Premarket Gainers – Nasdaq 100
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microchip Technology Inc.</td>
<td>+9.29%</td>
</tr>
<tr>
<td>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>)</td>
<td>+8.94%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>+8.44%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>+8.07%</td>
</tr>
<tr>
<td>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>+8.02%</td>
</tr>
</tbody>
</table>
</figure>
Top Premarket Losers – S&amp;P 500
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>-5.24%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.60%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.58%</td>
</tr>
<tr>
<td>Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-3.38%</td>
</tr>
<tr>
<td>Westinghouse Air Brake Technologies Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>)</td>
<td>-3.17%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">Apple, Amazon, Nvidia Rise In Monday Premarket As US, China Agree To 90-Day Tariff Truce: &#8216;Neither Side Wants A Decoupling&#8217;</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Photo: emin kuliyev/Shutterstock

Equities

Government

Regulations

Bonds

Forex

Econ #s

ETFs

AMZN

GEHC

MCHP

PowerShares DB US Dollar Index Bullish Fund

Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation

Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip"> during a market dip.</a>
Here's the latest transactions made by the congresswoman in early May.
What Happened: Greene was ranked as the 24th best-performing member of Congress based on their trades in 2024. The Congresswoman gained 30.2% for the year, <a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank">outperforming the S&amp;P 500 </a>gain of 24.9%.
With new trades placed throughout the early months of 2025, Greene could see huge returns again during the year.
Here are her most recent trades made on May 5, as shown on the <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725">Benzinga Government Trades page</a>. All purchases made were listed as between $1,001 to $15,000 unless otherwise indicated.
<ul>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</li>
<li>AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</li>
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)</li>
<li>Applied Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</li>
<li>Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</li>
<li>Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)</li>
<li>BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>)</li>
<li>BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>)</li>
<li>Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</li>
<li>Cummins Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>)</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>)</li>
<li>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)</li>
<li>Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>)</li>
<li>Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)</li>
<li>Frontline PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>)</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): two separate purchases of $1,001 to $15,000</li>
<li>Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>)</li>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</li>
<li>Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>)</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</li>
<li>JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)</li>
<li>Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>)</li>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Merck Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</li>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>)</li>
<li>ServiceNow Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>)</li>
<li>Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>): two separate purchases of $1,001 to $15,000</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</li>
<li>Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>): two separate purchases of $1,001 to $15,000</li>
<li>Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</li>
<li>Paychex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)</li>
<li>Impinj Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>)</li>
<li>Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)</li>
<li>Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>)</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</li>
<li>United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
<li>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</li>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)</li>
</ul>
In total, that's more than 50 different stocks bought and disclosed by Greene in the latest filing. Based on the purchase range of $1,001 to $15,000, this would make the transaction range over $50,000 and up to more than $800,000.
Read Also: <a href="https://www.benzinga.com/politics/25/04/45077654/bill-named-after-nancy-pelosi-could-ban-congress-members-from-trading-stocks-what-you-need-to-know-about-the-pelosi-act">Bill Named After Nancy Pelosi Could Ban Congress Members From Trading Stocks: What You Need To Know About The &#8216;PELOSI&#8217; Act</a>
Why It's Important: Members of Congress are allowed to buy and sell stocks as long as they properly disclose the transaction.
The process has drawn scrutiny from the public and retail investors as members of Congress could have inside information and time their trades accordingly. Committee assignments in particular, often draw red flags from investors.
Greene serves on the House Committee on Oversight and Accountability and the House Committee on Homeland Security with several subcommittee appointments. The congresswoman's past trade in technology and cybersecurity stocks has drawn attention with her role within Homeland Security.
Greene&#8217;s past trades of Palantir Technologies and a<a href="https://www.benzinga.com/25/03/44255172/marjorie-taylor-greene-buys-more-bitcoin-etf-shares-ahead-of-trumps-strategic-reserve-executive-order"> Bitcoin ETF </a>have drawn criticism along with the timing of her trades, as she is a close ally to President Donald Trump. 
When asked previously about buying stocks earlier this year that soared days later after Trump announced a pause to tariffs, Greene<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip"> brushed aside the criticism.</a>
&#8220;I think that criticism is laughable. President Trump has been talking about tariffs for decades,&#8221; Greene told reporters when asked about the trades at a recent town hall event in Georgia in a clip <a href="https://x.com/unusual_whales/status/1912456434081480777" target="_blank" rel="noreferrer noopener">shared </a>by Unusual Whales. The congresswoman used the opportunity to boast about her stock performance, which ranked her as one of the top trading members of Congress in 2024.
&#8220;I don&#8217;t place my buys and sells," Greene said, citing an agreement she has with her portfolio manager, who handles all the buying and selling of stocks. &#8220;He did a great job. Guess what he did. He bought the dip. And that&#8217;s what anybody that has financial sense does."
Greene also said her portfolio manager did not have inside information, everything was public and a potential tariff pause wasn&#8217;t a secret.
Sen. Josh Hawley (R-Mo.) has reintroduced legislation that would ban members of Congress from trading or holding individual stocks.
The bill is known as the Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act based on the first letter of each of the main words. The name takes aim at the congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.).  
&#8220;Members of Congress should be fighting for the people they were elected to serve — not day trading at the expense of their constituents,&#8221; Hawley&nbsp;<a href="https://www.hawley.senate.gov/hawley-reintroduces-pelosi-act-to-ban-congress-from-trading-stocks/" target="_blank" rel="noreferrer noopener">said</a>. &#8220;Americans have seen politician after politician turn a profit using information not available to the general public.&#8221;
Hawley said the bill will help &#8220;restore Americans&#8217; trust in our nation&#8217;s legislative body.&#8221;
Hawley&#8217;s bill is being reintroduced as President&nbsp;Donald Trump&nbsp;<a href="https://time.com/7280114/donald-trump-2025-interview-transcript/" target="_blank" rel="noreferrer noopener">said&nbsp;</a>he would support such a ban.
&#8220;Well, I watched Nancy Pelosi get rich through insider information, and I would be okay with it. If they send it to me, I would do it,&#8221; Trump told TIME.
Trump said he would sign the ban if the bill passes Congress.
While Pelosi makes headlines for her trades, it&#8217;s important to remember that<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener">&nbsp;it is both Republican</a>&nbsp;and Democratic members of Congress who are profiting from buying and selling stocks and options while in office, with some trades coming with questionable timing or having a connection to committees they serve on.
In 2024, a list of the top-performing traders in Congress included six Republicans and four Democrats.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-1024x330.png" alt="" class="wp-image-906796" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Photo: Shutterstock

Politics

AAPL

ADBE

AMAT

DELL

MELI

MSFT

NVDA

ODFL

PANW

PAYX

QCOM

SBUX

SCHW

Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought

– 60% of Participants with Prior Fibrate or Obeticholic Acid Treatment Achieve Biochemical Response with Livdelzi –
– New Evidence Supports Livdelzi Delivers Clinically and Statistically Significant Improvements in Pruritus –

Gilead Showcases Livdelzi's Efficacy And Tolerability In PBC, With 60% Response Rate Among Patients With Prior Fibrate Or OCA Use, At EASL 2025

– 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost 2 Years After Stopping Treatment –

Gilead's Bulevirtide Shows Durability In Chronic HDV, With 90% of Patients on Long-Term Therapy Maintaining Undetectable HDV RNA Off-Treatment

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in people with primary biliary cholangitis (PBC) –
– Additional presentations will showcase the potential for maintained virologic response following treatment with investigational bulevirtide in people with hepatitis delta virus (HDV) –
– Presentations in hepatitis B virus (HBV) and hepatitis C virus (HCV) will underscore Gilead's commitment to advancing scientific research and our understanding of viral hepatitis in the real-world setting –

Gilead To Present New Research To EASL Congress

President Donald Trump&#8216;s ongoing tariff policy changes have resulted in persistent market volatility and uncertainty. This has increased investors' appetite for stable, defensive stocks paying steady dividends. Dividend stocks have <a href="https://www.hartfordfunds.com/dam/en/docs/pub/whitepapers/WP106.pdf">contributed</a> significantly to overall market returns during the 1940s, 1960s, and 1970s, when average annual total returns were lower.
About seven months ago, a dividend investor <a href="https://www.reddit.com/r/dividends/comments/1fldncg/finally_hit_300k_goal/">shared</a> his monthly dividend income details and portfolio on r/Dividends — a Reddit discussion board with over 700,000 followers. The income report shared by the investor showed his monthly dividend income was $23,800, with a projected annual dividend income of just over $300,000.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
The investor, in his mid-50s, said he had about 150 holdings in his portfolio worth roughly $4.4 million. Asked how he was able to accumulate wealth to build such a large portfolio, he said it took him years to reach this milestone:
"Started at $3.50 per hour. Went back to school in my early 30s as did my wife. Definitely no inheritance and student loans to boot. Just 35 years of investing."
The investor said over $2 million of his wealth came from "decades of trading" biotech company Immunomedics, which was <a href="https://www.gilead.com/news/news-details/2020/gilead-sciences-to-acquire-immunomedics">bought</a> by Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) in 2020 for $88 per share.&nbsp;
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Let's take a look at some of the biggest holdings of the investor.
BlackRock Science and Technolgy Term Trust
BlackRock Science and Technology Term Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSTZ#NYSE">BSTZ</a>) was the biggest holding of the investor. The closed-end equity fund invests in science and technology companies and also generates income by selling call options on stocks in its portfolio. It has a dividend yield of about 9%.&nbsp;
Nuveen Real Asset Income and Growth Fund
The Nuveen Real Asset Income and Growth Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JRI#NYSE">JRI</a>) invests in companies related to infrastructure projects, facilities, and services, as well as REITs. Among the top holdings of the fund are Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>), Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>), Gaming and Leisure Properties (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>), Simon Property (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) and Omega Healthcare Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>).
DoubleLine Income Solutions Fund
DoubleLine Income Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSL#NYSE">DSL</a>) is a closed-end fund focusing on income-generating fixed-income securities. It yields about 12% and pays monthly.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Kayne Anderson Energy Infrastructure Fund&nbsp;
The Kayne Anderson Energy Infrastructure Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KYN#NYSE">KYN</a>) invests in midstream, natural gas &amp; LNG infrastructure, and power infrastructure companies. The fund has a dividend yield of over 8%.
Western Asset High Income Opportunity Fund
Another closed-end fund in the portfolio, Western Asset High Income Opportunity Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIO#NYSE">HIO</a>) primarily invests in high-yield corporate debt securities and preferred stocks for income generation and capital appreciation. The fund has a distribution rate of over 10%.&nbsp;
Voya Infrastructure, Industrials and Materials Fund
The Voya Infrastructure, Industrials and Materials Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDE#NYSE">IDE</a>) invests in companies in the infrastructure, industrials and materials sectors. Cisco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>), Uber (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) are among the fund's biggest holdings.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

BSTZ

CSCO

GLPI

TMUS

UBER

Dividend Investor in Mid-50s Making $23,800 A Month Shares Portfolio, Says He Started with $3.50/hour  —  'Just 35 Years of Investing'

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has fallen 4.44% since its last report. The company recently reported that it has 21.39 million shares sold short, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745600430_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 5.92%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Gilead Sciences?

Press Releases

Gilead Sciences Announces First Quarter 2025 Financial Results

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Comments

Gilead Sciences

매도 수량

Gilead Sciences (NASDAQ:GILD) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌